Observational Study Investigating the Effectiveness of Fentanyl Matrix in Relieving Pain and Improving Function in Patients With Osteoarthritis of the Knee or Hip
Information source: Janssen Korea, Ltd., Korea
ClinicalTrials.gov processed this data on August 20, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Pain; Osteoarthritis, Hip; Osteoarthritis, Knee
Intervention: fentanyl matrix (Drug); fentanyl matrix (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Janssen Korea, Ltd., Korea Official(s) and/or principal investigator(s): Janssen Korea, Ltd. Clinical Trial, Study Director, Affiliation: Janssen Korea, Ltd.
Summary
The purpose of this study is to investigate the utility of fentanyl matrix for the treatment
of pain due to osteoarthritis (OA) of knee or hip, which was not adequately controlled by
non-opioid analgesic (e. g. NSAIDs or COX-II inhibitors) or weak opioids [tramadol
HClacetaminophen, tramadol or codeine (or combinations with acetaminophen/ibuprofen)].
Clinical Details
Official title: Fentanyl Matrix for the Treatment of Pain Caused by Osteoarthritis of the Knee or Hip: Improvement of Pain and Function: Multicenter, Open-label, Prospective, Observational Study
Study design: Observational Model: Cohort, Time Perspective: Prospective
Primary outcome: Change in pain intensity from baseline through final evaluation as measured by Numeric Rating Scale
Secondary outcome: Improved pain relief as measured using the K-WOMAC scaleImprovement of sleep disturbance Impact of activity of daily activities measured by 5-point likert scale and social activities measured by 5-point likert scale Investigator and patient global assessment measured by 5-point likert scale Improved pain relief as measured using the CGI-I
Detailed description:
This study is a prospective, open-label, non-interventional study. The objective of this
study is to investigate the utility of fentanyl matrix after 8 week treatment of fentanyl
matrix for the treatment of pain due to osteoarthritis (OA) of knee or hip, which was not
adequately controlled by non-opioid analgesic (e. g. NSAIDs or COX-II selective inhibitors)
or weak opioids [tramadol HCl with acetaminophen, tramadol or codeine (or combination with
acetaminophen/ibuprofen)] in clinical practice according to the investigator's discretion.
This study will investigate the usefulness of fentanyl matrix based on improvement in pain
and function after Fentanyl matrix administration in patients who complained of pain caused
by osteoarthritis and indicated for Fentanyl matrix administration in clinical practice at
the investigator's discretion. This study will also measure the patients' functional
improvement through Korean Version of WOMAC. Observational study - No investigational drug
administered
Eligibility
Minimum age: 20 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
- Patients who complain of chronic pain caused by osteoarthritis of the knee or hip
persisting for 3 months or longer
- Patients who can fully observe the overall clinical study requirements including
K-WOMAC completion at the investigator's discretion
- Patients who complain of severe pain (NRS score = 7) because pain was not treated
enough with the previous analgesic
- Patients who have never been administered strong opioid analgesics over the last one
month
Exclusion Criteria:
- Patients with a history of the drug or alcohol abuse in the past or now
- Childbearing women who are pregnant or likely to be pregnant during the study period
and male subjects who are neither infertile nor willing to refrain from sexual
relations but whose partner does not conduct an effective contraception (implant,
injections, oral contraceptives, intrauterine device, etc.)
- Patients who are unable to use a transdermal system due to skin disease
- Patients with serious mental disorder
- Patients with history of hypersensitivity to opioid analgesics
- Patients with history of CO2 retention
- Patients who are not eligible for the study participation based on warnings,
precautions and contra medications in the package insert of the study drug at the
investigator's discretion
Locations and Contacts
Additional Information
Starting date: August 2008
Last updated: April 24, 2014
|